Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 3/20 | 0.56 |
| ▸ | CYP4Z1 | Q86W10 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7586516 | 0.98 | ASAH1 (0.58) | ASAH1CYP4Z1LMNATDP1SLC9A1 | |
| SCHEMBL5407957 | 0.75 | LMNA (0.63) | ASAH1LMNAALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL3715374 | 0.74 | ASAH1 (0.46) | ASAH1CYP4Z1 | |
| SCHEMBL7196863 | 0.74 | ASAH1 (0.42) | ASAH1CYP4Z1SMN1; SMN2TLR8 | |
| Decane SCHEMBL9491454 | 0.73 | ASAH1 (0.54) | ASAH1CYP4Z1LMNATDP1SLC9A1 | |
| SCHEMBL29795663 | 0.73 | ASAH1 (0.97) | ASAH1HSD17B10 | |
| SCHEMBL4359327 | 0.72 | ASAH1 (0.54) | ASAH1LMNATDP1ALOX15HSD17B10 | |
| SCHEMBL327149 | 0.72 | TDP1 (0.70) | LMNATDP1SLC9A1ALOX15SMN1; SMN2 | |
| SCHEMBL1488096 | 0.72 | TDP1 (0.48) | LMNATDP1ALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL15022038 | 0.72 | TDP1 (0.52) | LMNATDP1ALOX15HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101559-A1 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230391768-A2 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-12-07 | — | — | US | disclosed |
| US-20230183204-A9 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230148448-A9 | BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4041236-A1 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220127284-A1 | BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | GRAY NATHANAEL S (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220127260-A1 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220127246-A1 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| WO-2021067682-A1 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-1206260-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1206265-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1206260-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1194152-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6329380-B1 | PYRIMIDINE BENZIMIDIZAZOLE, PYRIMIDINEIMIDAZOLE OR PYRIDINE IMIDAZOLE COMPOUNDS FOR ANTICANCER AGENTS OR ATHEROSCLEROSIS | MERCK & CO., INC. | 2001-12-11 | — | — | US | disclosed |
| US-6316444-B1 | SRC kinase inhibitor compounds | MERCK & CO., INC. | 2001-11-13 | — | — | US | disclosed |
| WO-2001000214-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000207-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127260-A1 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | ASAH1 4240/4885CYP4Z1 1024/4885LMNA 4094/4885 |
| US-20220127246-A1 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | ASAH1 3840/4885CYP4Z1 953/4885LMNA 4105/4885 |
| US-20230183204-A9 | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | ASAH1 3840/4885CYP4Z1 953/4885LMNA 4105/4885 |
| US-20240101559-A1 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | CDK1, CDK11B, CDK11A | ASAH1 4573/4885CYP4Z1 807/4885LMNA 1711/4885 |
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | ASAH1 4240/4885CYP4Z1 1024/4885LMNA 4094/4885 |
| US-20230148448-A9 | BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | ASAH1 3803/4885CYP4Z1 556/4885LMNA 4533/4885 |
| US-20220127284-A1 | BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | ASAH1 3803/4885CYP4Z1 556/4885LMNA 4533/4885 |
| US-20230391768-A2 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | ASAH1 3995/4885CYP4Z1 874/4885LMNA 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.